Using a computer-based risk assessment tool to identify risk for chemotherapy-induced febrile neutropenia

Clinical Journal of Oncology Nursing

Volumn 14, Issue 1, 2010, Pages 87-91

  Miller, Kevin ^a  

^a MOUNT CARMEL HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; BREAST TUMOR; COMPARATIVE STUDY; COMPUTER ASSISTED DIAGNOSIS; FEASIBILITY STUDY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MIDDLE AGED; NEUTROPENIA; NURSING; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; DIAGNOSIS, COMPUTER-ASSISTED; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUTROPENIA; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 79952117499     PISSN: 10921095     EISSN: 1538067X     Source Type: Journal    
DOI: 10.1188/10.CJON.87-91     Document Type: Article

References (25)

1. Aapro, M.S., Cameron, D.A., Pettengell, R., Bohlius, J., Crawford, J., Ellis, M., Zielinski, C. (2006). EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. European Journal of Cancer, 42, 2433-2453. doi: 10.1016/j.ejca.2006.05.002
2. Ardizzoni, A., Favaretto, A., Boni, L., Baldini, E., Castiglioni, F., Antonelli, P., Paccagnella, A. (2005). Platinum-etoposide chemotherapy in elderly patients with small-cell lung cancer: Results of a randomized multicenter phase II study assessing attenuated-dose or full-dose with lenograstim prophylaxis. Journal of Clinical Oncology, 23, 569-575.
3. Bodey, G.P., Buckley, M., Sathe, Y.S., & Freireich, E.J. (1966). Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Annals of Internal Medicine, 64, 328-340.
4. Bonadonna, G., Moliterni, A., Zambetti, M., Daidone, M.G., Pilotti, S., Gianni, L., & Valagussa, P. (2005). 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: Cohort study. BMJ, 330(7485), 217.
5. Bosly, A., Bron, D., Van Hoof, A., De Bock, R., Berneman, Z., Ferrant, A., Verhoef, G. (2007). Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP. Annals of Hematology, 87, 277-283.
6. Caggiano, V., Weiss, R.V., Rickert, T.S., & Linde-Zwirble, W.T. (2005). Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer, 103, 1916-1924. doi: 10.1002/cncr.20983
7. Crawford, J., Dale, D.C., Kuderer, N.M., Culakova, E., Poniewierski, M.S., Wolff, D., & Lyman, G.H. (2008). Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: The results of a prospective nationwide study of oncology practice. Journal of the National Comprehensive Cancer Network, 6, 109-118.
8. Donohue, R. (2006). Development and implementation of a risk assessment tool for chemotherapy-induced neutropenia. Oncology Nursing Forum, 33, 347-352. doi: 10.1188/06.ONF.347-352
9. Doyle, A. (2006). Prechemotherapy assessment of neutropenic risk. Oncology (Williston Park), 20(10, Suppl.), 32-40.
10. Early Breast Cancer Trialists' Collaborative Group. (2005). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet, 365(9472), 1687-1717.
11. Freyer, G., Ligneau, B., & Trillet-Lenoir, V. (1998). Colony-stimulating factors in the prevention of solid tumors induced by chemotherapy in patients with febrile neutropenia. International Journal of Antimicrobial Agents, 10, 3-9.
12. Given, B.A., & Sherwood, P.R. (2005). Nursing sensitive patient outcomes-A white paper. Oncology Nursing Forum, 32, 773-784. doi: 10.1188/05.ONF.773-784
13. Hryniuk, W., Frei, E., III, & Wright, F.A. (1998). A single scale for comparing dose-intensity of all chemotherapy regimens in breast cancer: Summation dose-intensity. Journal of Clinical Oncology, 16, 3137-3147.
14. Kuderer, N.M., Dale, D.C., Crawford, J., Cosler, L.E., & Lyman, G.H. (2006). Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer, 106, 2258-2266.
15. Lyman, G.H., Dale, D.C., & Crawford, J. (2003). Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: A nationwide study of community practices. Journal of Clinical Oncology, 21, 4524-4531. doi: 10.1200/JCO.2003.05.002
16. Lyman, G.H., Dale, D.C., Friedberg, J., Crawford, J., & Fisher, R.I. (2004). Incidence and predictors of low chemotherapy dose- intensity in aggressive non-Hodgkin's lymphoma: A nationwide study. Journal of Clinical Oncology, 22, 4302-4311. doi: 10.1200/JCO.2004.03.213
17. Maxwell, C., & Stein, A. (2006). Implementing evidence-based guidelines for preventing chemotherapy-induced neutropenia: From paper to clinical practice. Community Oncology, 3, 530-536.
18. Moore, K., & Crom, D. (2006). Hematopoietic support with moderately myelosuppressive chemotherapy regimens: A nursing perspective. Clinical Journal of Oncology Nursing, 10, 383-388. doi: 10.1188/06.CJON.383-388
19. National Comprehensive Cancer Network. (2008a). NCCN Clinical Practice Guidelines in Oncology™: Myeloid growth factors [v.1.2008]. Retrieved from http://www.nccn.org/professionals/ physician_gls/f_guidelines.asp
20. National Comprehensive Cancer Network. (2008b). NCCN Clinical Practice Guidelines in Oncology™: Prevention and treatment of cancer-related infections [v.1.2008]. Retrieved from http://www.nccn.org/professionals/physician_gls/f_guidelines.asp
21. Pettengell, R., Schwenkglenks, M., & Bosly, A. (2008). Association of reduced relative dose intensity and survival in lymphoma patients receiving CHOP-21 chemotherapy. Annals of Hematology, 87, 429-430.
22. Scheithauer, W., Kornek, G.V., Raderer, M., Schüll, B., Schmid, K., Kovats, E., Depisch, D. (2003). Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. Journal of Clinical Oncology, 21, 1307-1312.
23. Smith, T.J., Khatcheressian, J., Lyman, G.H., Ozer, H., Armitage, J.O., Balducci, L., Wolff, A.C. (2006). 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. Journal of Clinical Oncology, 24, 3187-3205. doi: 10.1200/JCO.2006.06.4451
24. White, N., Maxwell, C., Michelson J., & Bedell, C. (2005). Protocols for managing chemotherapy-induced neutropenia in clinical oncology practices. Cancer Nursing, 28, 62-69. doi: 10.1097/00002820-200501000-00009
25. Wilson, B.J., & Gardner, A.E. (2007). Nurses' guide to understanding and implementing the National Comprehensive Cancer Network guidelines for myeloid growth factors. Oncology Nursing Forum, 34, 347-353. doi: 10.1188/07.ONF.347-353